ClinicalTrials.gg
Enrolling by invitationNCT06792617Updated Jan 24, 2025

Exercise Rehabilitation in Patients with Severe Cardiopulmonary Dysfunction on Extracorporeal Life Support

An Early Phase 1 interventional study of Mobility (Central or Femoral Cannulation) and Resistance Training in ExtraCorporeal Membrane Oxygenation (ECMO), Cardiopulmonary Function and Rehabilitation, sponsored by Institute for Extracorporeal Life Support. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Institute for Extracorporeal Life Support · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Short-term and long-term consequences of severe cardiac and/or lung dysfunction can be increased use of sedation, prolonged bedrest and immobility causing severe loss of muscle mass which could be a risk for muscle weakness, osteoporosis, and lowered endurance. The goal of this study is to show how a structured rehabilitation program can exhibit better short-term and long-term outcomes on patients who are treated with extracorporeal membrane oxygenation (ECMO).

Read the detailed description

I.Introduction

The long-term consequences of severe cardiac and/or lung dysfunction include: the increased use of sedation, increased parameters on the ventilator, and incidence of delirium. These sequelae are all associated with prolonged bed rest and immobility, which causes severe loss of muscle mass and bone density. Significant loss of muscle and bone causes patients to be at risk for muscle weakness, osteoporosis, and lowered endurance. Extracorporeal membrane oxygenation (ECMO) is a strategy used to mitigate severe cardiac and/or lung dysfunction. Briefly, during ECMO, blood passes through a mechanical circuit and external oxygenator, which removes carbon dioxide and adds oxygen. Blood is then re-infused by a pump to provide cardiovascular support upon return to the body. It provides gas exchange for patients when their own heart and/or lungs are unable to function adequately, and it has been shown to improve survival rates and outcomes in patients with severe respiratory failure.

The investigators hypothesize that patients with cardiac and/or lung dysfunction treated with ECMO who participate in this rehabilitation program will exhibit better short-term and long-term outcomes than patients who have not participated in this rehabilitation program. There are four aims to this study: patients who participate in this rehabilitation program will exhibit a (1) significantly increased rate of weaning from ECMO and from mechanical ventilation, (2) significantly decreased rate of major post-ECMO complications, (3) significantly increased time exercising and improvement and completion of activities of daily living [ADL], and (4) significant increase in quality of life, long-term outcomes, short physical performance battery, and rehabilitation outcomes.

II. Background This study's intended accomplishment will be to establish a multidisciplinary, structured exercise and rehabilitation program for patients on ECMO so that days on an ECMO circuit are reduced, quality of life is improved, post-ECMO complications are decreased, and positive long-term outcomes are increased. This is important because there is no standard of care established for a structured exercise program for patients on ECMO. These patients are primarily bed bound for the majority of their illness in the early stages; if early implementation of a structured exercise regimen is started then the amount of time it takes patients to return to their physical physiological baseline will be decreased, thus improving their quality of life.

A thorough review of the literature indicates that there is a critical lack of studies of rehabilitation, movement, or physical activity in the ECMO patient population. Furthermore, a structured rehabilitation program for ECMO patients simply does not exist. The use of a structured resistant exercise program in this population has not been studied. Thus, overcoming this deficiency is extremely important for the 10% of intensive care unit (ICU) admissions with cardiac and respiratory failure across the nation, specifically those who are placed on ECMO.

Approximately 30 studies exist in the literature that describe rehabilitation in the ECMO patient population. Briefly, these studies in adults with severe lung dysfunction have shown that participation in rehabilitation programs incorporating mobility training and physical (PT) and occupational therapy (OT) significantly improve functional and physiological outcomes and decrease muscle wasting, sedation requirements, and length of stay. The patients that participate in rehabilitation also increase endurance and have full stabilization of the cardiopulmonary system and full recovery of neurological functions. Most importantly, it has been shown that patients with severe lung dysfunction who enter a rehabilitation program decrease mortality, and they are more likely to be discharged home.

III. Rationale There is a need for randomized controlled trials to study methods for rehabilitation in the ECMO population, and this proposal serves as the first step towards that goal. The investigators firmly believe that the activities proposed here will beneficially impact the ECMO patient population by improving physiological responses, physical function, and psychosocial well-being. In bed-ridden and immobile adults, exercise and movement are important in reducing risk factors such as obesity, insulin resistance, and general deconditioning. The evidence base for this program can be found in both the basic and clinical science literature of several patient populations: adult and pediatric burns, geriatric and frail, bed rest and antigravity (via National Aeronautics and Space Administration [NASA] studies), post-cardiac arrest, and traumatic brain injury (TBI). Hence, the investigators have formed a team of thought leaders from these areas to create a personalized rehabilitation program in the ECMO population.

This study will advance our knowledge in how a structured exercise program effects ECMO patients in their short- and long-term outcomes. There will be an advancement of knowledge in the physiological benefits of exercising ECMO patients. The verticalization into daily nursing care, mobility exercises, PT/OT, and resistance training will give the investigators a better understanding of the components that help keep muscle wasting minimal and help decrease a patient's length of stay.

Decreased muscle wasting and length of stay, decreased risk of mortality, and decreased sedation requirements will increase the likelihood that patients will have a full cardiopulmonary and neurological recovery. Longer treatment periods also translate into significant costs in dollars but, also in human cost/value.

SECTION B: RESEARCH PLAN

IV. Study Objectives The objectives of this study are to complete the highest intensity exercise and activity as tolerated by patients to maximize their progression of strength, function, and out of bed activity. In doing this, the investigators will also reduce the risk for potential of skin breakdown on common areas associated with decubitus pressure injuries and prolonged bedrest. In this study, the investigators will be utilizing the VitalGo Total Lift Bed (TLB) V5 for vertical positioning to provide a better potential for hemodynamic response to activities to include: strength training, mobility tasks, and functional activities like ADLs.

02

Conditions studied

  • ExtraCorporeal Membrane Oxygenation (ECMO)
  • Cardiopulmonary Function
  • Rehabilitation

Keywords

  • Extracorporeal membrane oxygenation (ECMO)
  • Rehabilitation exercise program
03

In context

Lead sponsor

Institute for Extracorporeal Life Support is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >or equal to 18 years old
  2. On ECMO (VV and/or VA) for cardiopulmonary dysfunction/failure
  3. Admitted to Lung Recovery Intensive Care Unit (LRICU) or Cardiovascular Intensive Care Unit (CVICU).
  4. Richmond Agitation and Sedation Scale (RASS) greater than or equal to a score of -2 or greater.

Exclusion criteria

Exclusion Criteria--

  1. Hemodynamically unstable as determined by clinical care team (including but not limited to: oxygen saturation \<90%, below target range of mean arterial pressure despite vasoactive or mechanical support, prone positioning, use of mechanical assist device (such as the intra-aortic balloon pump [IABP] or ventricular assist device [VAD]), active management of intracranial hypertension with abnormal intracranial pressure, spinal precautions, uncontrolled seizures, unstable major fracture, large open surgical wound, known controlled active bleeding).
  2. Unable to utilize the VitalGo Total Lift BedTM (TLB, Catalog No. V5, Miramar FL) (e.g., height restrictions [>228 cm], weight restrictions [>425 lbs])
  3. Pregnant or breast feeding.
  4. Anticipated transfer to another hospital within 72 hours.
  5. Not anticipated to survive more than 24 hours.
  6. Unable to obtain from either patient or legally authorized representative (LAR).
  7. Patients in the ICU but not on ECMO upon enrollment.
  8. Patients actively awaiting transplant (heart/lung) without potential for weaning from ECMO.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Exercise Group

    The exercise group will complete the highest intensity exercise and activity as tolerated to maximize their progression of strength, function, and out of bed. This group will also be utlizing the VitalGo Total Lift Bed (TLB) V5 for vertical positioning to provide a better potential for hemodynamic response to activities to include: strength training, mobility tasks, and functional activities like Activities of Daily Living (ADL).

    Other: Mobility (Central or Femoral Cannulation) · Other: Resistance Training

Interventions

  • OtherMobility (Central or Femoral Cannulation)

    Functional Mobility \& ADL's 1. Assisted sitting with progression to unassisted; ADL's 2. Assisted standing with progression to unassisted; ADL's 1. VitalGo bed will be used if unsafe/unable to perform assisted standing. 2. Leg press (VitalGo bed) 3. Ambulation; ADL's

  • OtherResistance Training

    Repetitions will be counted and documented per session per structured exercise.

06

What researchers measure

Primary outcomes

  1. Timing of exercises

    Time spent exercising per each session of rehabilitation program

    Time frame: From enrollment to 3-month follow-up

Secondary outcomes

  1. Mobility

    Maximum Heart Rate (bpm)

    Time frame: From enrollment to 3-month follow-up

  2. Mobility

    Blood Pressure (mmHg)

    Time frame: From enrollment to 3-month follow-up

  3. Mobility

    Respiratory Rate (bpm)

    Time frame: From enrollment to 3-month follow-up

  4. Mobility

    Borg Rating of Perceived Exertion (RPE)--measured on a scale from 6 to 20, where 6 represents "no exertion at all" and 20 represents "maximal exertion"

    Time frame: From enrollment to 3-month follow-up

  5. Mobility

    Steps taken in one minute

    Time frame: From enrollment to 3-month follow-up

  6. Mobility

    Time spent standing away from bed (minutes)

    Time frame: From enrollment to 3-month follow-up

  7. Function

    Functional Independence Measure (FIM) from Activities of Daily Living (ADL). Each ADL will be graded per the FIM Instrument using the disability measure definitions from Total Assistance to Complete Independence.

    Time frame: From enrollment to 3-month follow-up

  8. Resistance Training

    Repetitions will be counted and documented per session per exercise. Grip strength will be tested using a hand dynamometer. The subject will be seated with their elbows at his/her side and flexed at right angles, and their wrists will be at a neutral position. The grip strength of the dominant hand will be tested as the average of three trials

    Time frame: From enrollment to 3-month follow-up

Other outcomes

  1. Quality of Life (QOL)

    The Patient-Reported Outcomes Measurement Information System-29 is a validated and reliable questionnaire that assesses seven health domains: physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance. This profile measurement using a standardized T-score system, where scores are interpreted relative to the general US population, with a mean of 50 and a standard deviation of 10; higher scores generally indicate greater impairment in most domains, except for physical function and social participation where higher scores indicate better functioning.

    Time frame: From enrollment to 3-month follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Kang D, Lim J, Kim BG, Nam H, Kim Y, Kang E, Kim S, Shim S, Lee M, Yoon J, Lee H, Shin SH, Park HY, Cho J. Psychometric validation of the Korean Patient-Reported Outcome Measurement Information System (PROMIS)-29 Profile V2.1 among patients with chronic pulmonary diseases. J Thorac Dis. 2021 Oct;13(10):5752-5764. doi: 10.21037/jtd-21-591. PubMed 34795924 ↗
  • Fisher CJ, Namas R, Seelman D, Jaafar S, Homer K, Wilhalme H, Young A, Nagaraja V, White ES, Schiopu E, Flaherty K, Khanna D. Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):49-56. Epub 2019 Sep 4. PubMed 31498073 ↗
  • Eggmann S, Verra ML, Luder G, Takala J, Jakob SM. Effects of early, combined endurance and resistance training in mechanically ventilated, critically ill patients: A randomised controlled trial. PLoS One. 2018 Nov 14;13(11):e0207428. doi: 10.1371/journal.pone.0207428. eCollection 2018. PubMed 30427933 ↗
  • Hayes K, Holland AE, Pellegrino VA, Young M, Paul E, Hodgson CL. Early rehabilitation during extracorporeal membrane oxygenation has minimal impact on physiological parameters: A pilot randomised controlled trial. Aust Crit Care. 2021 May;34(3):217-225. doi: 10.1016/j.aucc.2020.07.008. Epub 2020 Oct 7. PubMed 33039302 ↗
  • Hayes K, Holland AE, Pellegrino VA, Mathur S, Hodgson CL. Acute skeletal muscle wasting and relation to physical function in patients requiring extracorporeal membrane oxygenation (ECMO). J Crit Care. 2018 Dec;48:1-8. doi: 10.1016/j.jcrc.2018.08.002. Epub 2018 Aug 7. PubMed 30118978 ↗
  • Batycka-Stachnik D, Piwoda A, Darocha T, Spiewak M, Kosinski S, Jarosz A, Hymczak H, Sanak T, Galazkowski R, Piatek J, Konstanty-Kalandyk J, Drwila R. Problems and challenges in the early period of rehabilitating patients with severe hypothermia treated using ecmo support. Wiad Lek. 2016;69(3 pt 2):489-494. PubMed 27717931 ↗
  • Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. Erratum In: JAMA. 2016 Jul 19;316(3):350. doi: 10.1001/jama.2016.6956. JAMA. 2016 Jul 19;316(3):350. doi: 10.1001/jama.2016.9558. PubMed 26903337 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for May 2025, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 24, 2025
StartActual
Oct 25, 2024
Primary completionEst.
May 2025
CompletionEst.
Dec 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792617
Lead sponsor
Institute for Extracorporeal Life Support
Responsible party
Linda Sousse (Director of Research, Institute for Extracorporeal Life Support) — Principal investigator
First posted
Jan 24, 2025
Start date
Oct 25, 2024
Primary completion
May 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 24, 2025

Study contacts

Linda E Sousse, PhD, MBA
principal investigator · Institute for Extracorporeal Life Support

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion